Allergan Aesthetics has secured European regulatory approval for Boey (trenibotulinumtoxinE), a rapid-onset, short-duration neuromodulator indicated for temporary improvement of frown lines in adults. The approval marks the first commercial availability of a botulinum toxin engineered for faster onset (claimed to begin within 24–48 hours) and shorter duration (~8 weeks) compared to standard formulations.